EZH2 and acute myeloid leukemia: Collectively, EZH2 dysregulation caused by mutation and under‐expression identifies specific subtypes of AML EZH2 mutation predicts clinical outcome in AML, whereas EZH2 expression may guide the treatment choice between transplantation and chemotherapy.